Presidential Determination on Major Drug Transit or Major Illicit Drug Producing Countries for Fiscal Year 2026
Record date: 2025-09-17
Presidential Determination No. 2025-12 of September 8, 2025 Presidential Determination on Major Drug Transit or Major Illicit Drug Producing Countries for Fiscal Year 2026 Memorandum for the Secretary of State By the authority vested in me as President by the Constitution and the laws of the United States, including section 706(1) of the Foreign Relations Authorization Act, Fiscal Year 2003 ( Public Law 107-228 ) (FRAA), I hereby identify the following countries as major drug transit or major illicit drug producing countries: Afghanistan, The Bahamas, Belize, Bolivia, Burma, the People's
What this record contains
- Federal Register document
- 2025-18078
- Publication date
- 2025-09-17
- Citation
- 90 FR 44953
- Issuing office
- Executive Office of the President
Official record excerpt
Presidential Determination No. 2025-12 of September 8, 2025 Presidential Determination on Major Drug Transit or Major Illicit Drug Producing Countries for Fiscal Year 2026 Memorandum for the Secretary of State By the authority vested in me as President by the Constitution and the laws of the United States, including section 706(1) of the Foreign Relations Authorization Act, Fiscal Year 2003 ( Public Law 107-228 ) (FRAA), I hereby identify the following countries as major drug transit or major illicit drug producing countries: Afghanistan, The Bahamas, Belize, Bolivia, Burma, the People's Republic of China (PRC), Colombia, Costa Rica, the Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, India, Jamaica, Laos, Mexico, Nicaragua, Pakistan, Panama, Peru, and Venezuela. A country's presence on the foregoing list is not necessarily a reflection of its government's counterdrug efforts or level of cooperation with the United States. Consistent with the statutory definition of a major drug transit or major illicit drug producing country set forth in sections 481(e)(2) and 481(e)(5) of the Foreign Assistance Act of 1961, as amended (Public Law 87-195) (FAA), the reason countries are placed on the list is the combination of geographic, commercial, and economic factors that allow drugs or precursor chemicals to be transited or produced, even if a government has engaged in robust and diligent narcotics control and law enforcement measures. Pursuant to section 706(2)(A) of the FRAA, I hereby designate Afghanistan, Bolivia, Burma, Colombia, and Venezuela as having failed demonstrably during the previous 12 months to both adhere to their obligations under international counternarcotics agreements and to take the measures required by section 489(a)(1) of the FAA. Included with this determination are justifications for the designations of Afghanistan, Bolivia, Burma, Colombia, and Venezuela, as required by section 706(2)(B) of the FRAA. I have also determined, in accordance with the provisions of section 706(3)(A) of the FRAA, that United States assistance to Bolivia, Burma, Colombia, and Venezuela is vital to the national interests of the United States. Transnational organized crime's trafficking of fentanyl and other deadly illicit drugs into the United States has created a national emergency, including a public health crisis in the United States that remains the leading cause of death for Americans ages 18 to 44. More than 40 percent of Americans know someone who has died from an opioid overdose, and in 2024 the United States averaged over 200 deaths daily due to illicit drugs. This remains unacceptable, and my Administration is deploying every aspect of American power and unprecedented resources to defeat this threat to our Nation. First, I have secured our borders using the full range of law enforcement and military resources necessary to safeguard our Nation's security and sovereignty. For the first time in 4 years, our border is no longer an open sieve for drug terrorist cartels, human traffickers, and all others who would do our country harm. American lives are being saved, with overdose deaths finally starting to recede significantly for the first time in over a decade. I have also marshalled United States economic strength to compel greater cooperation from our North American neighbors to confront the drug threat and do their part. In Canada, Prime Minister Mark Carney responded by ( printed page 44954) appointing a fentanyl czar and proposing legislation to increase the inspection powers of law enforcement, but more action is needed to stop fentanyl and other drugs from crossing our border and to arrest drug criminals exploiting Canadian territory. In Mexico, President Claudia Sheinbaum has increased cooperation to confront the powerful cartels that poison both our countries with drugs and violence. Mexico has surged 10,000 National Guard troops to our shared border, achieved major fentanyl and precursor chemical seizures, and transferred 29 high-value targets—including major cartel figures—to United States custody to stand trial for their crimes. My Administration has worked closely with President Sheinbaum to achieve the most secure southwest border in history, saving lives and protecting communities from the scourge of fentanyl. This surge in Mexico's efforts must be sustained and institutionalized. Much more remains to be done by Mexico's government to target cartel leadership, along with their clandestine drug labs, precursor chemical supply chains, and illicit finances. Over the next year, the United States
The excerpt is reproduced from the public federal record and may omit later sections, tables, signatures or attachments. Open the official source for the complete text.
Questions for accountability
- What legal authority does this foreign policy action cite?
- Which agencies or officials were directed to act?
- What measurable implementation, cost, deadline or later court action followed?
How to use this page
This is a source-record entry, not a truth-rating by itself. It preserves the action, date and original government publication so it can be connected to later claims, implementation records, court decisions, costs and measurable outcomes. Editorial claim reviews on this site use separate finding labels and explain the evidence for those findings.